Dive Brief:
- Last week, Zydelig (idelalisib) was approved by the FDA for treatment of several types of blood cancer, including chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL) and small lymphocytic lymphoma (SLL).
- Onco360 will become a distributor for Zydelig, making the specialty pharmacy a part of Gilead’s very selective distribution network.
- Onco360 is focused on being a leader in the specialty oncology pharmacy market and sees Zydelig as an important addition to its portfolio.
Dive Insight:
Undoubtedly, the global oncology market is outpacing other markets and growing rapidly, with sales expected to reach $47 billion this year. Onco360 is positioning itself as a premiere pharmacy and clinical solutions company. Not only does Zydelig offer a convenient oral treatment option -- it provides a secondary treatment option for the more than 250,000 Americans who have CLL, FL or SLL.